ACTU: Oral elraglusib advances to trials, targeting improved survival and synergy in tough cancers
Oral elraglusib is advancing to clinical trials after demonstrating significant survival benefits and synergy with RAS inhibitors in hard-to-treat cancers. The oral pivot aims to improve patient exposure and convenience, with accelerated trials planned for multiple indications and a parallel pediat…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.